Qiagen (NYSE:QGEN) Releases Q1 2025 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its first quarter 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.550- for the period, compared to the consensus earnings per share estimate of 0.490. The company issued revenue guidance of $483.0 million-, compared to the consensus revenue estimate of $464.8 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. UBS Group reduced their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday. Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Jefferies Financial Group reissued a “buy” rating and issued a $52.50 target price (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $46.67 price target (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Qiagen presently has an average rating of “Hold” and an average price target of $47.71.

Qiagen Trading Up 5.4 %

QGEN stock opened at $40.33 on Tuesday. The business has a fifty day moving average price of $40.20 and a 200 day moving average price of $41.91. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The stock has a market capitalization of $8.96 billion, a price-to-earnings ratio of 112.29, a P/E/G ratio of 2.39 and a beta of 0.62.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.